Scientific Publication

A scientific breakthrough reveals a reversible cause for sarcopenia, offering the first real hope for a drug therapy to restore strength for millions of seniors.

Palo Alto's Atropos Health just published 12 studies in six months using AI, revealing insights on everything from GLP-1s to Crohn's. It's a new paradigm for medicine.

A new publication on Oncotelic's Sapu003 isn't just science; it's a critical de-risking event validating a manufacturing and drug delivery platform.

After a personal revelation, a veteran OB-GYN proposes sexual health as a core pillar of women's medicine, challenging decades of clinical silence.

D&D Pharmatech's zabopegdutide shows fast liver improvement independent of weight loss, a key differentiator in the crowded, multi-billion dollar MASH market.

Peer-reviewed data confirms Telix's theranostic approach for advanced prostate cancer, de-risking its Phase 3 trial and setting the stage for a new competitor.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

A Boston biotech is making waves with a novel drug and a rapid-screening platform, a one-two punch designed to eliminate drug-resistant cancer stem cells.

A new study reveals AI acts not as a replacement for thought, but as a cognitive amplifier. The key is how we use it—and how we protect our new digital footprint.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

A new benchmark reveals a startling gap: while one AI detector spots 98% of tampered images, Meta's own tool misses nearly two-thirds. What does this mean for trust online?

A new study reveals the thriving, high-risk market for compounded weight-loss drugs. Even after FDA shortages ended, some clinics use unregulated suppliers.

A Dutch med-tech firm's sutureless device, validated in a key trial, could make bypass surgery faster, safer, and more accessible via robotics.

South Korea's HIGHER Corp. unveils preclinical data for HILO WAVE®, a dual-hyaluronic acid booster that may bypass the inflammatory pathways of competitors.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.

A startling case study suggests lifelong heat exposure may build resilience against Alzheimer's. Now, medical researchers are turning to infrared saunas.

Revel's new enzyme reverses a hallmark of aging. This isn't just a lab success; it's a strategic move challenging the very definition of 'irreversible'.

A new medical report confirms artificial stone dust causes a fatal, fast-acting lung disease, finding safety controls inadequate and sparking calls for a ban.

A breakthrough study shows a wearable ear device can stimulate nerves to enhance the body’s natural clotting, offering a drug-free future for saving lives.

An AI infrastructure firm just used its own tech to design safer painkillers, tackling the liver toxicity risks of common drugs. What does this mean for pharma?